GB002, Inc.
Seralutinib
Pulmonary Arterial Hypertension
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for Seralutinib in Pulmonary Arterial Hypertension are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06274801: Phase 3 trial, sponsor GB002, Inc., drug Seralutinib. Primary completion date 2026-12 (estimated).”